Insulin resistant diabetes mellitus in a girl with mild Rabson-Mendenhall syndrome: efficacy of sodium glucose co-transporter 2 inhibitor
Diabetology International · 2025-01 · 16 (1) · 182-187
DOI: 10.1007/s13340-024-00773-y ↗Kurz gefasst
Fallbericht in der Zeitschrift Diabetology International, online erschienen am 15.11.2024. Verfasst von Yohei Masunaga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-Ku, Hamamatsu, 431-3192 Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Agency for Medical Research and Development.
Themen: Diabetes mellitus
Abstract (Originalsprache)
We report a beneficial effect of a sodium glucose co-transporter 2 (SGLT2) inhibitor in the management of insulin resistant diabetes mellitus (IRDM) in a Japanese girl with mild Rabson-Mendenhall syndrome (RMS). At 10 2/12 years of age, she was referred to us because of glucosuria, and was found to have marked acanthosis nigricans and RMS-like facial features such as proptosis, large ears, full lips, and gingival hypertrophy, but not other clinical features frequently found in RMS. At 11 9/12 years of age, her blood HbA1c level, though it remained ~ 6.5% until then, increased to 7.9% with pubertal development. She was treated with an SGLT2 inhibitor and metformin, which ameliorated overt hyperglycemia in the afternoon and the evening (postprandial time) as well as obvious hypoglycemia in the early morning (before breakfast), and reduced her blood HbA1c to 5.5%. Whole exome sequencing revealed probably disease-causing c.2465 T > C:p.(Leu822Pro) of paternal origin and c.3038C > T:p.(Pro1013Leu) of maternal origin in INSR. These findings imply the usefulness of SGLT2 inhibitor in the treatment of IRDM. It is likely that SGLT2 inhibitor mitigated hyperglycemia by increasing the urine glucose excretion and prevented severe hypoglycemia probably because of attenuated hyperinsulinemia in the absence of overt hyperglycemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-Ku, Hamamatsu, 431-3192 Japan.
- Department of Regional Medical Care Support, Hamamatsu University School of Medicine, Hamamatsu, 431-3192 Japan.
- Department of Pediatrics, Hamamatsu Medical Center, Hamamatsu, 432-8580 Japan.
- Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, 431-3192 Japan.
ORCID-Profile: Yohei Masunaga
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Masunaga, Y., Kinjo, K., Murai, Y., Fujisawa, Y., Saitsu, H., & Ogata, T. (2025). Insulin resistant diabetes mellitus in a girl with mild Rabson-Mendenhall syndrome: efficacy of sodium glucose co-transporter 2 inhibitor. Diabetology International, 16(1), 182-187. https://doi.org/10.1007/s13340-024-00773-y
Vancouver
Masunaga Y, Kinjo K, Murai Y, Fujisawa Y, Saitsu H, Ogata T. Insulin resistant diabetes mellitus in a girl with mild Rabson-Mendenhall syndrome: efficacy of sodium glucose co-transporter 2 inhibitor. Diabetology International. 2025;16(1):182-187. doi:10.1007/s13340-024-00773-y
BibTeX
@article{Masunaga2025,
author = {Masunaga, Yohei and Kinjo, Kenichi and Murai, Yuki and Fujisawa, Yasuko and Saitsu, Hirotomo and Ogata, Tsutomu},
title = {Insulin resistant diabetes mellitus in a girl with mild Rabson-Mendenhall syndrome: efficacy of sodium glucose co-transporter 2 inhibitor},
journal = {Diabetology International},
year = {2025},
volume = {16},
number = {1},
pages = {182--187},
doi = {10.1007/s13340-024-00773-y}
}
EUVIMED